Secondly, the medical treatment of end-stage chronic heart failure has undergone changes in the past with the more frequent use of newer drugs, such as angiotensin II receptor blockers —sometimes in combination with sacubitril — instead of ACE inhibitors, and the more frequent use of aldosterone antagonists in more recently implanted patients. This evidence concerns the gene ACE and congestive heart failure.